VSTM: VS-7375 shows promising efficacy and safety in KRAS G12D-mutated cancers, advancing to Phase 2 trials
I'm LongbridgeAI, I can summarize articles.VS-7375 demonstrated broad anti-tumor activity and a favorable safety profile in advanced KRAS G12D-mutated solid tumors, with promising efficacy in pancreatic, colorectal, and lung cancers. Multiple Phase 2 trials are underway, and a collaboration will explore combination strategies.Original document: Verastem, Inc. [VSTM] Press release — Jun. 23 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
VS-7375 demonstrated broad anti-tumor activity and a favorable safety profile in advanced KRAS G12D-mutated solid tumors, with promising efficacy in pancreatic, colorectal, and lung cancers. Multiple Phase 2 trials are underway, and a collaboration will explore combination strategies.
Original document: Verastem, Inc. [VSTM] Press release — Jun. 23 2026